Abstract
Limited knowledge has been reported regarding the performance of plasma metabolomics for predicting lung cancer prognosis. In this chapter, we compared the plasma metabolomics of lung cancer patients with differential disease-free survival (DFS, <3 years vs. >4 years) using liquid chromatography–mass spectrometry. We identified 29 survival-related aqueous metabolites but no lipid metabolites. Amino acids and organic acids constitute the majority of these metabolites. The metabolic pathways of these metabolites were cysteine and methionine metabolism and arginine biosynthesis. The Cox proportional hazards regression models confirmed the predictive values of 18 metabolites for DFS, while the phosphocholine and xanthine showed independent predictive values. Regarding cancer phenotypes, thelephoric acid, phosphocholine, inosine, 3-hydroxyanthranilic acid, hypoxanthine, xanthine, and 4-hydroxybenzoic acid showed good correction with lymph node metastasis. Taken together, plasma metabolomics is a powerful tool for identifying prognostic metabolites of lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Global Burden of Disease 2019 Cancer Collaboration (2021) Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol 2021:420. https://doi.org/10.1001/jamaoncol.2021.6987
Pietzner M, Stewart ID, Raffler J, Khaw KT, Michelotti GA, Kastenmuller G et al (2021) Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med 27(3):471–479. https://doi.org/10.1038/s41591-021-01266-0
Rinschen MM, Ivanisevic J, Giera M, Siuzdak G (2019) Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol 20(6):353–367. https://doi.org/10.1038/s41580-019-0108-4
Johnson CHIJ, Siuzdak G (2016) Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol 17:7. https://doi.org/10.1038/nrm.2016.25
Jasbi P, Wang D, Cheng SL, Fei Q, Cui JY, Liu L et al (2019) Breast cancer detection using targeted plasma metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 1105:26–37. https://doi.org/10.1016/j.jchromb.2018.11.029
Ahn HS, Yeom J, Yu J, Kwon YI, Kim JH, Kim K (2020) Convergence of plasma metabolomics and proteomics analysis to discover signatures of high-grade serous ovarian cancer. Cancers (Basel) 12(11). https://doi.org/10.3390/cancers12113447
Liu X, Zhang M, Cheng X, Liu X, Sun H, Guo Z et al (2020) LC-MS-based plasma metabolomics and Lipidomics analyses for differential diagnosis of bladder cancer and renal cell carcinoma. Front Oncol 10:717. https://doi.org/10.3389/fonc.2020.00717
Lin X, Lecuyer L, Liu X, Triba MN, Deschasaux-Tanguy M, Demidem A et al (2021) Plasma metabolomics for discovery of early metabolic markers of prostate cancer based on ultra-high-performance liquid chromatography-high resolution mass spectrometry. Cancers (Basel) 13(13). https://doi.org/10.3390/cancers13133140
Nezami Ranjbar MR, Luo Y, Di Poto C, Varghese RS, Ferrarini A, Zhang C et al (2015) GC-MS based plasma metabolomics for identification of candidate biomarkers for hepatocellular carcinoma in Egyptian cohort. PLoS One 10(6):e0127299. https://doi.org/10.1371/journal.pone.0127299
Huang S, Guo Y, Li ZW, Shui G, Tian H, Li BW et al (2021) Identification and validation of plasma Metabolomic signatures in precancerous gastric lesions that Progress to cancer. JAMA Netw Open 4(6):e2114186. https://doi.org/10.1001/jamanetworkopen.2021.14186
Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T et al (2011) Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 71(21):6590–6600. https://doi.org/10.1158/0008-5472.CAN-11-0885
Ke C, Hou Y, Zhang H, Fan L, Ge T, Guo B et al (2015) Large-scale profiling of metabolic dysregulation in ovarian cancer. Int J Cancer 136(3):516–526. https://doi.org/10.1002/ijc.29010
Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M et al (2021) MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res 49(W1):W388–WW96. https://doi.org/10.1093/nar/gkab382
Wishart DS (2019) Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev 99(4):1819–1875. https://doi.org/10.1152/physrev.00035.2018
Ang JE, Pandher R, Ang JC, Asad YJ, Henley AT, Valenti M et al (2016) Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to phase I trial evaluation. Mol Cancer Ther 15(6):1412–1424. https://doi.org/10.1158/1535-7163.MCT-15-0815
Swietlik EM, Ghataorhe P, Zalewska KI, Wharton J, Howard LS, Taboada D et al (2021) Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. Eur Respir J 57(4). https://doi.org/10.1183/13993003.03201-2020
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wang, P., Yuan, Y., Qiu, M. (2023). Identification of Plasma Metabolites Associated with Lung Cancer Survival. In: Huang, T., Yang, J., Tian, G. (eds) Liquid Biopsies. Methods in Molecular Biology, vol 2695. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3346-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3346-5_12
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3345-8
Online ISBN: 978-1-0716-3346-5
eBook Packages: Springer Protocols